#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Search all trials

Find therapies in clinical trials near you – page 5

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Hormone-dependent prostate cancer

Recruiting

Registered drugNo placebo

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Apalutamide

Contact Research Centre

Bladder cancer

Recruiting

Registered drugNo placebo

Durvalumab and Chemotherapy in Adults With Muscle-Invasive Bladder Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Neuroendocrine carcinoma

Recruiting

Registered drugNo placebo

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

A study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Infliximab

Contact Research Centre

Acute promyelocytic leukaemia

Recruiting

Registered drugNo placebo

Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

Registered drugNo placebo

France

Participants:0–17 years
Substances:Arsenic Trioxide

Contact Research Centre

HER2 positive breast cancer

Recruiting

Registered drugNo placebo

Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Ductal adenocarcinoma of pancreas

Recruiting

InvestigationalNo placebo

A study of daraxonrasib (RMC-6236) compared to observation in patients with resected pancreatic cancer following chemotherapy

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:(12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE

Contact Research Centre

Progressive supranuclear palsy

Recruiting

Registered drug

A study to evaluate the safety and effectiveness of NIO752 in patients with progressive supranuclear palsy

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Sodium Chloride

Contact Research Centre

Neoplasm malignant

Recruiting

Registered drugNo placebo

A study of S-241656 and a drug combination in patients with certain types of cancer involving KRAS, BRAF, or other RAS/MAPK mutations

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cetuximab

Contact Research Centre

Hereditary haemochromatosis

Recruiting

Investigational

A study to evaluate the effectiveness and safety of vamifeport in adults with hereditary hemochromatosis

Investigational

France

Participants:18–64 years · 65+ years
Substances:VAMIFEPORT TRIHYDROCHLORIDE

Contact Research Centre

Bladder cancer

Recruiting

Registered drugNo placebo

A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Docetaxel

Contact Research Centre

Ovarian cancer

Recruiting

Registered drugNo placebo

Phase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:INCB123667

Contact Research Centre

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.